技術指標
指標
數值
方向
MACD(12,26,9)
-0.008
賣出
RSI(14)
40.107
中性
STOCH(KDJ)(9,3,3)
39.051
中性
ATR(14)
0.052
低波動
CCI(14)
-66.111
中性
Williams %R
72.054
賣出
TRIX(12,20)
-0.754
賣出
StochRSI(14)
48.639
賣出
搜尋
Mustang Bio Inc
MBIO添加自選
0.570USD
-0.024-3.97%
收盤 07-31 16:00（美東）報價延遲15分鐘
4.32M總市值
虧損本益比TTM
關鍵數據
0.597今開
0.618最高
11.07K成交量
虧損本益比TTM
--本益比動
--股利TTM
0.15%換手率
0.594昨收
0.560最低
4.43K成交額
虧損本益比靜
0.50市淨率
0.00%股息率 TTM
-17.29%ROA
7.00052週最高
0.28量比
-15.75M淨利潤
7.58M總股本
-0.4798每股盈餘TTM
2.08Beta
-44.62%ROE
0.53152週最低
9.73%振幅
--毛利率
4.32M總市值
-3.12回報/風險
4.97%風險率
TradingKey Mustang Bio Inc股票評分
單位: USD 更新時間: 2026-07-31操作建議
Mustang Bio Inc當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名196/385位。機構持股佔比非常高，中期看，股價處於下降通道。近一個月，市場表現非常差，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Mustang Bio Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Mustang Bio Inc亮點
亮點風險
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
估值低估
公司最新PE估值-1.19，處於3年歷史低位
機構加倉
最新機構持股664.20K股，環比增加22.79%
分析師目標
基於
0
分析師
--
評級
--
目標均價
--
漲幅空間
Mustang Bio Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
技術指標
移動平均線
指標
數值
方向
MA5
0.587
賣出
MA10
0.593
賣出
MA20
0.635
賣出
MA50
0.671
賣出
MA100
0.717
賣出
MA200
0.927
賣出
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Mustang Bio Inc簡介
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
公司代碼MBIO
公司Mustang Bio Inc
CEOLitchman (Manuel)
網址https://www.mustangbio.com/
公司股東
相關品種
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%熱門品種
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
常見問題
Mustang Bio Inc(MBIO)的當前股價是多少？
Mustang Bio Inc(MBIO)的當前股價是 0.57。
Mustang Bio Inc 的股票代碼是什麼？
Mustang Bio Inc的股票代碼是MBIO。
Mustang Bio Inc股票的52週最高點是多少？
Mustang Bio Inc股票的52週最高點是7.00。
Mustang Bio Inc股票的52週最低點是多少？
Mustang Bio Inc股票的52週最低點是0.53。
Mustang Bio Inc的市值是多少？
Mustang Bio Inc的市值是4.32M。
Mustang Bio Inc(MBIO)股票的每股收益（EPS TTM）是多少
Mustang Bio Inc(MBIO)股票的每股收益（EPS TTM）是-0.39。